<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJBD</journal-id><journal-title-group><journal-title>Open Journal of Blood Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-3180</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojbd.2024.142007</article-id><article-id pub-id-type="publisher-id">OJBD-133862</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Pulmonary and Orbital
   Bifocal IgG4 Disease: Case Report and Literature Review
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abasse</surname><given-names>Moussa Ounteini</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mamane</surname><given-names>Daou</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bad&amp;#233;</surname><given-names>Malam-Abdou</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Brah</surname><given-names>Souleymane</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amadou</surname><given-names>Djibrilla Almoustapha</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yerima</surname><given-names>Salifou</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Seraphin</surname><given-names>Adjoh Komi</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Etienne</surname><given-names>Devin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Habeeb</surname><given-names>Mahmoud</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Anas</surname><given-names>Mehdaoui</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>Pulmonology Department, Niamey National Hospital, Niamey, Niger</addr-line></aff><aff id="aff1"><addr-line>Department of Pneumology and Thoracic Cancerology, Eure-Seine Hospital, &amp;amp;#201;vreux, France</addr-line></aff><aff id="aff3"><addr-line>Department of Hematology, National Hospital of Niamey, FSS-UAM of Niamey, Niamey, Niger</addr-line></aff><aff id="aff2"><addr-line>Department of Internal Medicine, General Reference Hospital, FSS-UAM of Niamey, Niamey, Niger</addr-line></aff><aff id="aff5"><addr-line>Pneumology Department, Sylvanus Olympio University Hospital of Lom&amp;amp;#233;, Lom&amp;amp;#233;, Togo</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>05</month><year>2024</year></pub-date><volume>14</volume><issue>02</issue><fpage>59</fpage><lpage>64</lpage><history><date date-type="received"><day>3,</day>	<month>April</month>	<year>2024</year></date><date date-type="rev-recd"><day>16,</day>	<month>June</month>	<year>2024</year>	</date><date date-type="accepted"><day>19,</day>	<month>June</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  <b>Introduction:</b> IgG4 disease is an orphan, fibro-inflammatory autoimmune disease of recent discovery whose thoracic involvement is rarer. We report a case of Pulmonary and orbital bifocal IgG4 disease with a review of the literature. 
  <b>Observation:</b> This is a 71-year-old patient with a history of hypertension, dyslipidemia, smoking cessation at 15 PA, with progressive dyspnoea, weight loss of 4 kg with PS = 0 for 2 months. The thoracic CT scan revealed 3 pseudotumoral lung lesions of the LIG, LID and LM. The histology of the two CT-guided lung biopsies and the LIG wedge had objectified inflammatory lesions without signs of malignancy. The evolution was marked by the occurrence of a right orbital edema. The cerebral scanner found a voluminous right orbital inflammatory pseudotumor. Biopsy with histology found fibroinflammatory lesions with lymphoplasmacytic infiltrates and positive immunolabeling with anti-IgG4 antibodies. The PET scanner had objectified pulmonary and pleural parenchymal consolidations and moderately hypermetabolic mediastinal ADP with max SUV between 3 and 6. The patient was put on corticosteroid therapy with a favorable outcome. 
  <b>Conclusion:</b> IgG4 disease is rare and difficult to diagnose despite well-defined and consensual diagnostic criteria and classification. The discovery of new biomarkers facilitates the diagnosis and monitoring of patients. Well-codified corticosteroid therapy is effective but possibility of recurrence. The current challenge remains the lack of data on the follow-up of these patients to assess the risk of neoplasia (lymphoma).
 
</p></abstract><kwd-group><kwd>Orphan Disease</kwd><kwd> Thoracic IgG4 Disease</kwd><kwd> Autoimmunity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>IgG4 disease is a rare and recently discovered autoimmune disease. It is an inflammatory and fibrosing disease affecting one or more organs. It is characterized by clinical signs, tumor lesion(s), sometimes an elevation in the serum IgG4 level, and positivity of anti-IgG4 antibodies. The diagnosis of IgG4 disease is very difficult, hence diagnostic criteria and an ACR/EULAR classification were established, thus facilitating the diagnosis [<xref ref-type="bibr" rid="scirp.133862-ref1">1</xref>] . The diagnosis of thoracic IgG4 disease is even more rare and difficult. This thoracic involvement is very difficult to distinguish from pulmonary neoplasia both clinically and visually [<xref ref-type="bibr" rid="scirp.133862-ref2">2</xref>] . The definitive diagnosis is based on immunohistochemistry of fragments of the affected organ. We report a case of bifocal pulmonary and orbital IgG4 disease with a review of the literature.</p></sec><sec id="s2"><title>2. Case Report</title><p>This was a 71-year-old patient, smoking at 15 PA who had stopped smoking, who had progressively worsening dyspnea over the past 2 months, weight loss of 4 kg with PS = 0. Chest CT highlighting 3 pseudo pulmonary lesions tumors of the left lower lobe (LIG), the right lower lobe (LID) and the middle lobe (LM) (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>The standard biological assessment was normal. MPO type ANCAs = 80 IU/ml. Two CT-guided lung biopsies of the LID and LM lesions were performed with objective histological examination of subacute inflammatory and necrotic lesions, without signs of malignancy. The patient underwent an atypical pulmonary resection (wedge) of the LIG with histological examination revealing fibrous and inflammatory changes without granulomatosis or neoplasia. CT of the skull and abdominopelvic was normal. Bronchial endoscopy and histology of bronchial biopsies were normal. EFRs were normal. The evolution was marked</p><p>by the occurrence of right orbital edema with on cerebral CT a voluminous expansive process intra orbital supero-temporal right retro, latero bulbar intra conal infiltrating the lacrimal gland, the external oculo motor muscle and extended to the region upper eyelid taking moderate contrast with exophthalmos related to an inflammatory pseudotumor. Biopsy of the orbital mass was performed. Histology revealed fibroinflammatory lesions, with lymphoplasmacytic infiltrates. On PET scan the lung lesions and hilar lymph nodes were moderately hypermetabolic with SUV max of hilar ADP between 3.2 and 3.6, SUV max of LM = 4.2, SUV max of LID = 6 and SUV max of LIG = 4.1. Immunostaining with anti-CD138 antibodies revealed numerous plasma cells. Immunostaining with anti-IgG4 antibodies marked 30% of CD138 plasma cells. The diagnosis of IgG4 disease was retained. The patient was put on long-term corticosteroid therapy with favorable progress.</p></sec><sec id="s3"><title>3. Discussion</title><p>IgG4 disease is little known and underdiagnosed. The positive diagnosis is guided by the association of characteristic criteria with imaging, serology, and histology. The diagnosis is confirmed by the predominance of plasma cells and the positivity of anti-IgG4 antibodies on immunohistochemistry [<xref ref-type="bibr" rid="scirp.133862-ref2">2</xref>] . Respiratory damage is generally discovered incidentally. The patient is male and 71 years old. Male predominance is reported in the literature in 60% of cases with an average age between 60 and 70 years. The patient presented with progressively worsening dyspnea and weight loss of 4 kg in 2 months. In the literature, respiratory symptoms are nonspecific and patients are asymptomatic in 75% of cases [<xref ref-type="bibr" rid="scirp.133862-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref5">5</xref>] . IgG4 disease can affect one or more organs with single organ involvement in 19% of cases. The involvement of several organs mainly concerns the salivary glands (70%), lacrimal glands (60%), lymph nodes (60%), pancreas (25%). Chest involvement is less common (23%) of cases. Our patient has bifocal thoracic and orbital involvement unlike other studies with bifocal thoracic and pancreatic involvement predominating in 50% of cases [<xref ref-type="bibr" rid="scirp.133862-ref4">4</xref>] . The chest scan lesions were pseudo-tumorous pulmonary parenchymal lesions of LIG, LID and LM. Among pulmonary locations, parenchymal involvement is most frequently found in studies with intra or interlobular reticulations, traction bronchiectasis, honeycombing and aspects of organizing pneumonia [<xref ref-type="bibr" rid="scirp.133862-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref6">6</xref>] . Pulmonary vascular damage such as aneurysm, necrotizing angiitis or stenosis of the pulmonary arteries are also described [<xref ref-type="bibr" rid="scirp.133862-ref7">7</xref>] . Thoracic involvement of IgG4 disease was the subject of the ACR/EULAR classification [<xref ref-type="bibr" rid="scirp.133862-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref9">9</xref>] . The standard biological assessment carried out in the patient was normal; notably neutrophils and eosinophils. The MPO type ANCA dosage was positive at 80 IU/ml without signs of vasculitis on the histology of the 2 CT-guided biopsies and the wedge. Serum IgG4 was 1.47 g/L (Normal ≤ 1.35 g/L). In the literature, the increase in plasma IgG4 level is not specific for IgG4 disease but constitutes a criterion for diagnostic guidance. Our patient had an IgG4/IgG plasma cell ratio &gt; 50%. Several studies have shown that this IgG4/IgG ratio ≥ 40% seems to be a good argument in favor of IgG4 disease [<xref ref-type="bibr" rid="scirp.133862-ref10">10</xref>] . New biological biomarkers have been identified for diagnosis and prognosis [<xref ref-type="bibr" rid="scirp.133862-ref11">11</xref>] . These are serum levels of IgG2, soluble IL-2 receptors and chemokine C-C motif ligand 18 [<xref ref-type="bibr" rid="scirp.133862-ref12">12</xref>] ; eotaxin-3 [<xref ref-type="bibr" rid="scirp.133862-ref12">12</xref>] ; circulating plasmablasts [<xref ref-type="bibr" rid="scirp.133862-ref5">5</xref>] . In our case, the histology associated with the immunohistochemistry of the biopsy of the lung lesions but especially the right orbit had made it possible to make the diagnosis of IgG4 disease as reported by some others [<xref ref-type="bibr" rid="scirp.133862-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref15">15</xref>] .</p><p>The clinical, paraclinical and histopathological characteristics of IgG4 disease were the subject of an international consensus adopted in 2011 and revised in 2020 [<xref ref-type="bibr" rid="scirp.133862-ref12">12</xref>] . The disease is considered confirmed, probable, or possible depending on the number of criteria met. In our patient, the criteria met were radiological, histological and immunohistochemical, therefore, criteria 1 + 2 + 3 of <xref ref-type="table" rid="table1">Table 1</xref> make the diagnosis definite. The histopathological features of G4 immunoglobulin-related disease are listed in <xref ref-type="table" rid="table2">Table 2</xref> [<xref ref-type="bibr" rid="scirp.133862-ref16">16</xref>] .</p><p>These criteria were completed during an international consensus in 2012 [<xref ref-type="bibr" rid="scirp.133862-ref9">9</xref>] . The main differential diagnoses of IgG4 disease are ANCA vasculitis, Gougerot-Sj&#246;gren syndrome, sarcoidosis, organizing pneumonia, eosinophilic pneumonia, Castleman disease and cancers, particularly malignant lymphomas [<xref ref-type="bibr" rid="scirp.133862-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.133862-ref17">17</xref>] .</p><p>Therapeutically, the management of IgG4 disease is mainly based on corticosteroid therapy. Our patient was placed on long-term corticosteroid therapy with good clinical progress.</p><p>There are several treatment regimens depending on the schools and authors. The following treatment consensus is the most used: starting dose, prednisolone at a dosage of 0.6 to 1 mg/kg per day for two to four weeks, then gradual reduction until stopping. The total duration is 12 weeks [<xref ref-type="bibr" rid="scirp.133862-ref18">18</xref>] . According to literature data, under this treatment regimen, recurrence is found in approximately 25% of patients [<xref ref-type="bibr" rid="scirp.133862-ref19">19</xref>] . In cases of corticosteroid dependence, immunosuppressants can be used [<xref ref-type="bibr" rid="scirp.133862-ref16">16</xref>] . IgG4 disease is a recently discovered disease and there is little data on its evolution. Indeed, IgG4 disease would be an increased risk factor for neoplasia, especially lymphoma [<xref ref-type="bibr" rid="scirp.133862-ref20">20</xref>] , hence the importance of rigorous monitoring to assess this risk.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Diagnostic criteria for immunoglobulin-related disease type G4 (IgG4)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Signs of organ(s) diffusely or partially enlarged, or in nodular form.</th></tr></thead><tr><td align="center" valign="middle" >Serum IgG4 level &gt; or equal to 1.35 g/l.</td></tr><tr><td align="center" valign="middle" >Histopathological examination: lymphoplasmacytic infiltrate with sclerosis IgG4+/IgG+ cell ratio &gt; 40%, and &gt; or equal to 10 IgG4+ plasma cells/HPF.</td></tr><tr><td align="center" valign="middle" >Confirmed diagnosis: 1 + 2 + 3; probable 1 + 3; possible 1 + 2 HPF: high power field.</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Histopathological characteristics of disease linked to immunoglobulin type G4 (IgG4)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Lymphocytic infiltrate with predominance of IgG4-positive plasma cells and CD4+ T lymphocytes;</th></tr></thead><tr><td align="center" valign="middle" >Storiform fibrosis or fibrosis consisting of proliferating spindle-shaped cells around infiltrating lymphocytes;</td></tr><tr><td align="center" valign="middle" >Obstructive phlebitis;</td></tr><tr><td align="center" valign="middle" >Refers to a carcass wheel pattern with a sometimes spiral center, and bands of fibrosis emanating from it with an irregular tangled weave somewhat resembling that of a straw mat.</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>4. Conclusion</title><p>IgG4 disease is an orphan disease and pulmonary involvement remains little known in pulmonology. The clinical symptoms are non-specific. Imaging reveals pseudotumors. Diagnosis is based on immunohistochemistry. Corticosteroid therapy is effective. IgG4 disease appears to be a risk factor for lymphoma, hence the importance of rigorous monitoring.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s6"><title>Cite this paper</title><p>Moussa Ounteini, A., Daou, M., Malam-Abdou, B., Souleymane, B., Djibrilla Almoustapha, A., Salifou, Y., Adjoh Komi, S., Devin, E., Mahmoud, H. and Mehdaoui, A. (2024) Pulmonary and Orbital Bifocal IgG4 Disease: Case Report and Literature Review. Open Journal of Blood Diseases, 14, 59-64. https://doi.org/10.4236/ojbd.2024.142007</p></sec></body><back><ref-list><title>References</title><ref id="scirp.133862-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Schleinitz, N., Briantais, A. and Ebbo, M. (2020) IgG4-Related Disease: Diagnostic Criteria Evolution toward the 2019 ACR/EULAR Classification Criteria. &lt;i&gt;La Revue de M&amp;#233;decine Interne&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;41, 814-821. &lt;br&gt;https://doi.org/10.1016/j.revmed.2020.06.015</mixed-citation></ref><ref id="scirp.133862-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y., Cai, S., Dong, L. and Umehara, H. (2022) Update on Classification, Diagnosis, and Management of Immunoglobulin G4-Related Disease. &lt;i&gt;Chinese Medical Journal&lt;/i&gt;, 135, 381-392. &lt;br&gt;https://doi.org/10.1097/CM9.0000000000001891</mixed-citation></ref><ref id="scirp.133862-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Yamada, K., Yamamoto, M., Saeki, T., Mizushima, I., Matsui, S., Fujisawa, Y., &lt;i&gt;et al&lt;/i&gt;. (2017) New Clues to the Nature of Immunoglobulin G4-Related Disease: A Retrospective Japanese Multicenter Study of Baseline Clinical Features of 334 Cases. &lt;i&gt;A&lt;/i&gt;&lt;i&gt;r&lt;/i&gt;&lt;i&gt;thritis Research &amp; Therapy&lt;/i&gt;, 19, 262. &lt;br&gt;https://doi.org/10.1186/s13075-017-1467-x</mixed-citation></ref><ref id="scirp.133862-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yi, E.S., Sekiguchi, H., Peikert, T., &lt;i&gt;et al&lt;/i&gt;. (2012) Pathologic Manifestations of IgG4-Related Lung Disease. &lt;i&gt;Seminars in Diagnostic Pathology&lt;/i&gt;, 29, 219-225. &lt;br&gt;https://doi.org/10.1053/j.semdp.2012.07.002</mixed-citation></ref><ref id="scirp.133862-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Berrier, A., Gomez, E., Essari, L.-A., Soler, J., Petit, I., Pierre, C., &lt;i&gt;et al&lt;/i&gt;. (2021) La maladie associ&amp;#233;e aux IgG4: Une cause rare de pneumopathie infiltrante hypox&amp;#233;miante s&amp;#233;v&amp;#232;re. &lt;i&gt;Revue des Maladies Respiratoires&lt;/i&gt;, 38, 530-534. &lt;br&gt;https://doi.org/10.1016/j.rmr.2021.02.071</mixed-citation></ref><ref id="scirp.133862-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ryu, J.H., Sekiguchi, H. and Yi, E.S. (2012) Pulmonary Manifestations of Immunoglobulin G4-Related Sclerosing Disease. &lt;i&gt;European Respiratory Journal&lt;/i&gt;, 39, 180-186. &lt;br&gt;https://doi.org/10.1183/09031936.00025211</mixed-citation></ref><ref id="scirp.133862-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, Y., Shao, L., Ruan, W., Jin, J., Xu, H., Ying, K., &lt;i&gt;et al&lt;/i&gt;. (2019) Pulmonary Vascular Involvement of IgG4-Related Disease: Case Series with a PRISMA-Compliant Systemic Review. &lt;i&gt;Medicine&lt;/i&gt; (&lt;i&gt;Baltimore&lt;/i&gt;), 98, e14437. &lt;br&gt;https://doi.org/10.1097/MD.0000000000014437</mixed-citation></ref><ref id="scirp.133862-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">M&amp;#252;ller, R., Habert, P., Ebbo, M., Graveleau, J., Groh, M., Launay, D., Audia, S., &lt;i&gt;et al&lt;/i&gt;. (2020) L&amp;#8217;atteinte thoracique est fr&amp;#233;quente au cours de la maladie associ&amp;#233;e aux IgG4: &amp;#201;tude multicentrique r&amp;#233;trospective. &lt;i&gt;La Revue de M&amp;#233;decine Interne&lt;/i&gt;, 41, 27-28. &lt;br&gt;https://doi.org/10.1016/j.revmed.2020.10.052</mixed-citation></ref><ref id="scirp.133862-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wallace, Z.S., Naden, R.P., Chari, S., &lt;i&gt;et al&lt;/i&gt;. (2020) The 2019 American College of Rheumatology/European League against Rheumatism Classification Criteria for IgG4-Related Disease. &lt;i&gt;Arthritis &amp; Rheumatology&lt;/i&gt;, 72, 7-19.</mixed-citation></ref><ref id="scirp.133862-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Deshpande, V., Zen, Y., Chan, K.J., Yi, E.E., Sato, Y., Yoshino, T., &lt;i&gt;et al&lt;/i&gt;. (2012) Consensus Statement on the Pathology of IgG4-Related Disease. &lt;i&gt;Modern Pathology&lt;/i&gt;, 25, 1181-1192. &lt;br&gt;https://doi.org/10.1038/modpathol.2012.72</mixed-citation></ref><ref id="scirp.133862-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Tang, J., Cai, S., Ye, C. and Dong, L. (2020) Biomarkers in IgG4-Related Disease: A Systematic Review. &lt;i&gt;Seminars in Arthritis and Rheumatism&lt;/i&gt;, 50, 354-359. &lt;br&gt;https://doi.org/10.1016/j.semarthrit.2019.06.018</mixed-citation></ref><ref id="scirp.133862-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Takanashi, S., Kikuchi, J., Sasaki, T., Akiyama, M., Yasuoka, H., Yoshimoto, K., &lt;i&gt;et al&lt;/i&gt;. (2021) Lymphadenopathy in IgG4-Related Disease: A Phenotype of Severe Activity and Poor Prognosis, with Eotaxin-3 as a New Biomarker. &lt;i&gt;Rheumatology&lt;/i&gt; (&lt;i&gt;O&lt;/i&gt;&lt;i&gt;x&lt;/i&gt;&lt;i&gt;ford&lt;/i&gt;), 60, 967-975. &lt;br&gt;https://doi.org/10.1093/rheumatology/keaa648</mixed-citation></ref><ref id="scirp.133862-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ebbo, M., Grados, A., &lt;i&gt;et al&lt;/i&gt;. (2012) Maladie systemique associee aux IgG4: Une pathologie emergente? Mise au point et revue de la litterature. &lt;i&gt;La Revue de M&amp;#233;dec&lt;/i&gt;&lt;i&gt;ine Interne&lt;/i&gt;, 33, 23-34. &lt;br&gt;https://doi.org/10.1016/j.revmed.2011.08.012</mixed-citation></ref><ref id="scirp.133862-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Bennis, R., Roy, T., Atto, Y.N. and Colin, M.I. (2020) La maladie syst&amp;#233;mique &amp;#224; IgG4, une cause rare de pancr&amp;#233;atite aig&amp;#252;e s&amp;#233;v&amp;#232;re. &lt;i&gt;Louvain M&amp;#233;dical&lt;/i&gt;, 139, 185-191.</mixed-citation></ref><ref id="scirp.133862-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Pellet, L., Coattrenec, Y., Moll, S. and Seebach, J.D. (2019) Maladie &amp;#224; IgG4: L&amp;#8217;exp&amp;#233;rience genevoise. &lt;i&gt;Revue M&amp;#233;dicale Suisse&lt;/i&gt;, 15, 736-741. &lt;br&gt;https://doi.org/10.53738/REVMED.2019.15.645.0736</mixed-citation></ref><ref id="scirp.133862-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Umehara, H., Okazaki, K., Kawa, S., Takahashi, H., Goto, H., Matsui, S., &lt;i&gt;et al&lt;/i&gt;. (2021) The 2020 Revised Comprehensive Diagnostic (RCD) Criteria for IgG4-RD. &lt;i&gt;Modern Rheumatology&lt;/i&gt;, 31, 529-533.</mixed-citation></ref><ref id="scirp.133862-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Matsui, S., Yamamoto, H., Minamoto, S., Waseda, Y., Mishima, M. and Kubo, K. (2016) Proposed Diagnostic Criteria for IgG4-Related Respiratory Disease. &lt;i&gt;Resp&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;ratory Investigation&lt;/i&gt;, 54, 130-132. &lt;br&gt;https://doi.org/10.1016/j.resinv.2015.09.002</mixed-citation></ref><ref id="scirp.133862-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Okazaki, K., Chari, S.T., Frulloni, L., Lerch, M.M., Kamisawa, T., Kawa, S., &lt;i&gt;et al&lt;/i&gt;. (2017) International Consensus for the Treatment of Autoimmune Pancreatitis. &lt;i&gt;Pancreatology&lt;/i&gt;, 17, 1-6. &lt;br&gt;https://doi.org/10.1016/j.pan.2016.12.003</mixed-citation></ref><ref id="scirp.133862-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Khosroshahi, A. and Stone, J.H. (2011) Treatment Approaches to IgG4-Related Systemic Disease. &lt;i&gt;Current Opinion in Rheumatology&lt;/i&gt;, 23, 67-71. &lt;br&gt;https://doi.org/10.1097/BOR.0b013e328341a240</mixed-citation></ref><ref id="scirp.133862-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Delteil, C., Chesnaisa, A.-L., Tasei, A.-M., Cohen-Pansieri, C., Naffaa, N. and Granier, G. (2016) Maladie &amp;#224; immunoglobuline G4 pulmonaire: Rapport de cas et revue de litt&amp;#233;rature. &lt;i&gt;Annales de Pathologie&lt;/i&gt;, 36, 218-221. &lt;br&gt;https://doi.org/10.1016/j.annpat.2016.02.001</mixed-citation></ref></ref-list></back></article>